NASDAQ$GOSS
Gossamer Bio Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Announced second quarter 2021 financial results and provided a corporate update.
Gossamer Bio reported cash, cash equivalents and marketable securities totaling $406 million as of June 30, 2021. The company's net loss for the quarter ended June 30, 2021, was $59.8 million, or $0.80 per share.
- Seralutinib and GB004 continue to enroll ongoing Phase 2 TORREY and SHIFT-UC clinical trials for Pulmonary Arterial Hypertension (PAH) and Ulcerative Colitis (UC), respectively
- Gossamer announced Seralutinib Open Label Extension Data in PAH Patients
- Gossamer to discontinue clinical development of GB1275
- Cash, cash equivalents and marketable securities totaled $406 million as of June 30, 2021
Headline financials
Revenue & EPS history
Gossamer Bio · Revenue · Quarterly
$0
Revenue by segment
Gossamer Bio · $17M total across 1 segment · Q1 2026
- Collaborators$17M—100.0%
Forward guidance
The Company expects the combination of current cash, cash equivalents and marketable securities, and access to its debt facility will be sufficient to fund its operating and capital expenditures into the second half of 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2021
-0.6%
Avg return
Earnings day
-1.3%
Avg return
5 days after
-1.1%
Avg return
30 days after
43%
13 / 30 earnings
Positive
+15.2%
Q4 2022
Best reaction
-15.6%
Q1 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.2% | -34.9% | -50.9% | |
| Q4 2025 | -10.8% | -21.0% | -5.5% | |
| Q3 2025 | +2.2% | +16.9% | +44.2% | |
| Q2 2025 | -8.5% | -18.9% | +15.7% | |
| Q1 2025 | +1.0% | +9.5% | +18.1% | |
| Q4 2024 | +0.0% | +6.0% | -38.4% | |
| Q3 2024 | -0.9% | -4.4% | -15.1% | |
| Q2 2024 | +4.3% | +7.5% | +12.5% | |
| Q1 2024 | -3.2% | -5.0% | -23.2% | |
| Q4 2023 | +4.1% | -4.8% | -26.2% | |
| Q3 2023 | -12.0% | +4.7% | +73.1% | |
| Q2 2023 | -7.0% | -9.3% | -24.7% | |
| Q1 2023 | +3.7% | -11.8% | -7.4% | |
| Q4 2022 | +15.2% | +5.7% | -0.5% | |
| Q3 2022 | -0.8% | -4.2% | -14.9% | |
| Q2 2022 | +4.6% | +6.5% | +13.7% | |
| Q1 2022 | +12.5% | +34.2% | +9.5% | |
| Q4 2021 | +3.7% | +1.0% | -2.8% | |
| Q3 2021 | -1.4% | -9.1% | -16.6% | |
| Q2 2021 | -0.8% | +9.5% | +18.9% | |
| Q1 2021 | -0.7% | -0.7% | +1.7% | |
| Q4 2020 | -9.4% | -5.5% | -11.6% | |
| Q3 2020 | -0.9% | -1.3% | +4.2% | |
| Q2 2020 | +5.1% | +2.4% | -1.1% | |
| Q1 2020 | -15.6% | -11.5% | -27.8% | |
| Q4 2019 | +5.5% | +5.7% | +40.0% | |
| Q3 2019 | -4.3% | -1.2% | +12.4% | |
| Q2 2019 | -2.5% | +3.2% | +2.6% | |
| Q1 2019 | +1.3% | +3.7% | -3.9% | |
| Q4 2018 | -4.9% | -10.8% | -30.1% | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro